Featured Research

from universities, journals, and other organizations

Alternative approaches to surgical valve replacement offer comparable outcomes

Date:
October 1, 2013
Source:
Society of Thoracic Surgeons
Summary:
Patients with aortic stenosis who are ineligible for surgical valve replacement as well as the traditional approach to transcatheter aortic valve replacement (TAVR) may have comparable outcomes when the surgeon uses an alternative access TAVR approach.

Patients with aortic stenosis who are ineligible for surgical valve replacement as well as the traditional approach to transcatheter aortic valve replacement (TAVR) may have comparable outcomes when the surgeon uses an alternative access TAVR approach, according to a study in the October 2013 issue of The Annals of Thoracic Surgery.

"Our experience demonstrated that cardiac surgeons and cardiologists must utilize a multitude of access options in TAVR to achieve minimal morbidity and mortality with excellent outcomes," said Vinod H. Thourani, MD, from Emory University in Atlanta and lead author of the study.

TAVR using the transfemoral (TF) approach (via the groin) was recently approved in the United States for inoperable or high-risk patients with aortic stenosis, the most common acquired valvular disease in adults. Aortic stenosis is characterized by a narrowing of the opening to the aortic valve. Surgical aortic valve replacement is the treatment of choice; however, 25% of patients may be ineligible for surgery for reasons such as frailty or additional disease.

TF TAVR was approved for these high-risk or inoperable patients, but some patients have too much disease in the femoral artery to permit using this approach.

To understand more about the outcomes from other TAVR approaches, Dr. Thourani and his colleagues at Emory conducted a single-center retrospective review of 44 inoperable patients who underwent alternative access TAVR from November 2011 to April 2012. Alternative access approaches included transapical (TA -- via the heart muscle), transaortic (TAo -- via the aorta), and transcarotid (TCa -- via the right common carotid artery) TAVR.

Of the 44 patients reviewed, 18 -- less than half -- were eligible for TF, while 11 underwent TA, 12 underwent TAo, and three underwent TCa procedures.

Thirty days after the TAVR procedures, the researchers found no difference among the groups in mortality and no incidents of myocardial infarction or stroke. Study participants implanted using a non-TF approach, however, experienced longer average lengths of hospital stays.

"What we have learned from this study," said Dr. Thourani, "is that the TAVR physician, be it a cardiologist or cardiac surgeon, should feel comfortable utilizing a variety of TAVR techniques. This will allow the most appropriate tailoring of the TAVR procedure for optimal patient outcomes."

The U.S. Food and Drug Administration recently announced its approval of alternative access approaches for TAVR using the Edwards Sapien Transcatheter Heart Valve, making the procedure available to an expanded group of patients who have inoperable aortic valve stenosis. The new device labeling removes references to specific access points now making it available for inoperable patients who require one of these alternative access points.


Story Source:

The above story is based on materials provided by Society of Thoracic Surgeons. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vinod H. Thourani, Rebecca L. Gunter, Soumya Neravetla, Peter Block, Robert A. Guyton, Patrick Kilgo, Stamatios Lerakis, Chandan Devireddy, Bradley Leshnower, Kreton Mavromatis, James Stewart, Amy Simone, Patricia Keegan, Tom C. Nguyen, John Merlino, Vasilis Babaliaros. Use of Transaortic, Transapical, and Transcarotid Transcatheter Aortic Valve Replacement in Inoperable Patients. The Annals of Thoracic Surgery, 2013; 96 (4): 1349 DOI: 10.1016/j.athoracsur.2013.05.068

Cite This Page:

Society of Thoracic Surgeons. "Alternative approaches to surgical valve replacement offer comparable outcomes." ScienceDaily. ScienceDaily, 1 October 2013. <www.sciencedaily.com/releases/2013/10/131001090004.htm>.
Society of Thoracic Surgeons. (2013, October 1). Alternative approaches to surgical valve replacement offer comparable outcomes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/10/131001090004.htm
Society of Thoracic Surgeons. "Alternative approaches to surgical valve replacement offer comparable outcomes." ScienceDaily. www.sciencedaily.com/releases/2013/10/131001090004.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins